Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Baillie Gifford & Co.

Baillie Gifford & Co. increased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 52.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,332,690 shares of the company's stock after acquiring an additional 456,853 shares during the quarter. Baillie Gifford & Co. owned approximately 1.57% of Progyny worth $22,989,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Leibman Financial Services Inc. boosted its position in Progyny by 100.7% during the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company's stock worth $1,096,000 after acquiring an additional 31,872 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Progyny by 15.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company's stock valued at $16,366,000 after purchasing an additional 132,672 shares during the last quarter. Aurora Investment Counsel acquired a new position in shares of Progyny in the 3rd quarter valued at $1,280,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Progyny in the 4th quarter valued at $989,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Stock Performance

Shares of NASDAQ PGNY traded down $0.68 during midday trading on Friday, hitting $23.20. The company's stock had a trading volume of 1,243,035 shares, compared to its average volume of 1,799,572. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $40.89. The firm's fifty day moving average price is $19.84 and its 200-day moving average price is $18.66. The firm has a market cap of $1.98 billion, a P/E ratio of 40.00, a P/E/G ratio of 2.37 and a beta of 1.34.

Analyst Ratings Changes

PGNY has been the topic of a number of research analyst reports. Truist Financial reiterated a "hold" rating and issued a $19.00 price target (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Barclays decreased their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Canaccord Genuity Group decreased their price target on shares of Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Progyny has an average rating of "Hold" and a consensus target price of $25.83.

Insider Activity

In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the firm's stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.